Benitec Biopharma
BNTC
7 hedge funds and large institutions have $797K invested in Benitec Biopharma in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
35% less capital invested
Capital invested by funds: $1.23M → $797K (-$436K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.3K |
| 2 |
Morgan Stanley
New York
|
+$8.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$30K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highbridge Capital Management
New York
| $410K | – | – | – |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $180K | – | – | – |
|
|
3
Morgan Stanley
New York
| $95K | +$8.29K | +15 | +6% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $87K | +$50.3K | +91 | +67% |
|
5
Renaissance Technologies
New York
| $21K | – | – | – |
|
|
AIC
6
Ameritas Investment Company
Lincoln,
Nebraska
| $3K | +$4.42K | +8 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $1K | -$2.76K | -5 | -63% |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$30K | -47 | Closed |
|
BNTC Hedge Fund Activity: Q4 2018 in Review
7 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2018, worth a combined $797K — down 35% from $1.23M a quarter earlier.
Fund positioning in BNTC was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $50.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $30K sold.
- 7 institutional investors held Benitec Biopharma (BNTC) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $797K of Benitec Biopharma stock for Q4 2018, down 35% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q4 2018 and 1 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q4 2018 was Susquehanna International Group, an estimated $50.3K added.
- The largest Benitec Biopharma seller in Q4 2018 was Citadel Advisors, an estimated $30K sold.
Based on aggregated 13F filings for Q4 2018.